FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313453457> ?p ?o ?g. }

• W4313453457 endingPage "5914" @default.
• W4313453457 startingPage "5907" @default.
• W4313453457 abstract "Bevacizumab (Avastin®) is a monoclonal antibody targeting the vascular endothelial growth factor (VEGF). Used alone or in combination with chemotherapy and/or immunotherapy, Avastin® has shown promising efficacy in many cancers. This study compared the efficacy and safety of TAB008 with Avastin® sourced from the EU (bevacizumab-EU), in patients with non-squamous non-small cell lung cancer (nsNSCLC). In this randomized, double-blind, multicenter, phase III similarity study, treatment naïve for metastatic lung cancer., EGFR wild-type, locally advanced, metastatic, or recurrent non-squamous, non-small cell, lung cancer (nsNSCLC) patients were enrolled and randomized (1:1) into TAB008 or Avastin® groups. Patients received TAB008 or Avastin® 15 mg/kg intravenously plus paclitaxel/carboplatin for 4–6 cycles followed by TAB008 or Avastin® 7.5 mg/kg until disease progression, unacceptable toxicity or death. The primary endpoint compared the objective response rate (ORR) within 6 cycles as read by an independent radiological review committee (IRRC). Secondary endpoints compared disease control rate (DCR) Within 6 cycles, duration of response (DoR), progression-free survival (PFS), a year overall survival rate (OSR), overall survival (OS), safety, immunogenicity, and steady-state pharmacokinetics. A total of 549 nsNSCLC patients were enrolled (277 in TAB008 group and 272 in Avastin® group). In the full analysis set, ORRs were 55.957% for TAB008 and 55.720% for Avastin®, and the ORR ratio was 1 (90% CI 0.89–1.14), well within the predefined equivalence margin of 0.75–1.33. No significant differences were found in DCR within 6 cycles (95.703% vs 95.367%, p = 0.8536), DoR (8.17 vs 7.3 months, p = 0.3526), PFS (9.10 vs. 7.97 months, p = 0.9457), 1 year overall survival rate (66.2% vs 68%, p = 0.6793), or OS (20.4 vs 17.6 months, p = 0.6549). Serious adverse events (SAEs) occurred in 37.55% (104/277) of patients in the TAB008 group and 34.32% (93/271) in the Avastin® group. Anti-drug antibodies were reported in 3 of 277 (1.08%) TAB008 patients, and 5 of 271 (1.85%) Avastin® patients, neutralizing antibody (Nab) was positive in 1 patient on Avastin®, which became negative upon follow-up. The steady-state trough concentrations (Cssmin) were 106.13 μg/mL in TAB008 group and 96.03 μg/mL in Avastin® groups, with the treatment group ratio of LS geometric means fully contained within the bioequivalence limits of 80.00–125.00% (90% CI was 101.74–120.05%). TAB008 is similar to Avastin® in terms of efficacy, safety, and pharmacokinetic parameters, with comparable immunogenicity. ClinicalTrials.gov number; NCT05427305." @default.
• W4313453457 created "2023-01-06" @default.
• W4313453457 creator A5003319796 @default.
• W4313453457 creator A5005099731 @default.
• W4313453457 creator A5006148444 @default.
• W4313453457 creator A5010596222 @default.
• W4313453457 creator A5014967397 @default.
• W4313453457 creator A5021242356 @default.
• W4313453457 creator A5038573737 @default.
• W4313453457 creator A5040747953 @default.
• W4313453457 creator A5043672686 @default.
• W4313453457 creator A5044454984 @default.
• W4313453457 creator A5047770529 @default.
• W4313453457 creator A5049760753 @default.
• W4313453457 creator A5062983293 @default.
• W4313453457 creator A5065499324 @default.
• W4313453457 creator A5078989023 @default.
• W4313453457 date "2023-01-03" @default.
• W4313453457 modified "2023-09-27" @default.
• W4313453457 title "Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study" @default.
• W4313453457 cites W1967738163 @default.
• W4313453457 cites W2039727128 @default.
• W4313453457 cites W2135192471 @default.
• W4313453457 cites W2145835533 @default.
• W4313453457 cites W2510374213 @default.
• W4313453457 cites W2582613071 @default.
• W4313453457 cites W2805354595 @default.
• W4313453457 cites W2909515204 @default.
• W4313453457 cites W2964048033 @default.
• W4313453457 cites W2998158023 @default.
• W4313453457 cites W3013347515 @default.
• W4313453457 cites W3025022288 @default.
• W4313453457 doi "https://doi.org/10.1007/s00432-022-04563-4" @default.
• W4313453457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36595042" @default.
• W4313453457 hasPublicationYear "2023" @default.
• W4313453457 type Work @default.
• W4313453457 citedByCount "0" @default.
• W4313453457 crossrefType "journal-article" @default.
• W4313453457 hasAuthorship W4313453457A5003319796 @default.
• W4313453457 hasAuthorship W4313453457A5005099731 @default.
• W4313453457 hasAuthorship W4313453457A5006148444 @default.
• W4313453457 hasAuthorship W4313453457A5010596222 @default.
• W4313453457 hasAuthorship W4313453457A5014967397 @default.
• W4313453457 hasAuthorship W4313453457A5021242356 @default.
• W4313453457 hasAuthorship W4313453457A5038573737 @default.
• W4313453457 hasAuthorship W4313453457A5040747953 @default.
• W4313453457 hasAuthorship W4313453457A5043672686 @default.
• W4313453457 hasAuthorship W4313453457A5044454984 @default.
• W4313453457 hasAuthorship W4313453457A5047770529 @default.
• W4313453457 hasAuthorship W4313453457A5049760753 @default.
• W4313453457 hasAuthorship W4313453457A5062983293 @default.
• W4313453457 hasAuthorship W4313453457A5065499324 @default.
• W4313453457 hasAuthorship W4313453457A5078989023 @default.
• W4313453457 hasBestOaLocation W43134534572 @default.
• W4313453457 hasConcept C126322002 @default.
• W4313453457 hasConcept C143998085 @default.
• W4313453457 hasConcept C168563851 @default.
• W4313453457 hasConcept C203092338 @default.
• W4313453457 hasConcept C2776256026 @default.
• W4313453457 hasConcept C2776694085 @default.
• W4313453457 hasConcept C2777802072 @default.
• W4313453457 hasConcept C2780739268 @default.
• W4313453457 hasConcept C71924100 @default.
• W4313453457 hasConceptScore W4313453457C126322002 @default.
• W4313453457 hasConceptScore W4313453457C143998085 @default.
• W4313453457 hasConceptScore W4313453457C168563851 @default.
• W4313453457 hasConceptScore W4313453457C203092338 @default.
• W4313453457 hasConceptScore W4313453457C2776256026 @default.
• W4313453457 hasConceptScore W4313453457C2776694085 @default.
• W4313453457 hasConceptScore W4313453457C2777802072 @default.
• W4313453457 hasConceptScore W4313453457C2780739268 @default.
• W4313453457 hasConceptScore W4313453457C71924100 @default.
• W4313453457 hasIssue "9" @default.
• W4313453457 hasLocation W43134534571 @default.
• W4313453457 hasLocation W43134534572 @default.
• W4313453457 hasLocation W43134534573 @default.
• W4313453457 hasOpenAccess W4313453457 @default.
• W4313453457 hasPrimaryLocation W43134534571 @default.
• W4313453457 hasRelatedWork W1983576003 @default.
• W4313453457 hasRelatedWork W2055244776 @default.
• W4313453457 hasRelatedWork W2387455091 @default.
• W4313453457 hasRelatedWork W2413020017 @default.
• W4313453457 hasRelatedWork W2417717847 @default.
• W4313453457 hasRelatedWork W2492137275 @default.
• W4313453457 hasRelatedWork W2794605011 @default.
• W4313453457 hasRelatedWork W3004966710 @default.
• W4313453457 hasRelatedWork W3029430426 @default.
• W4313453457 hasRelatedWork W4231596293 @default.
• W4313453457 hasVolume "149" @default.
• W4313453457 isParatext "false" @default.
• W4313453457 isRetracted "false" @default.
• W4313453457 workType "article" @default.